Metformin prevents dopaminergic neuron death in MPTP/P-induced mouse model of Parkinson's disease via autophagy and mitochondrial ROS clearance

International Journal of Neuropsychopharmacology

Volumn 19, Issue 9, 2016, Pages 1-11

  Lu, Ming ^a   Su, Cunjin ^a   Qiao, Chen ^a   Bian, Yaqi ^a   Ding, Jianhua ^a   Hu, Gang ^a,b,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING NORMAL UNIVERSITY   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

AMPK; Autophagy; Metformin; Mitochondrial ROS; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; CATECHOLAMINE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; METFORMIN; MICROTUBULE ASSOCIATED PROTEIN 1; PROBENECID; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; CORPUS STRIATUM; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; MICROGLIA; MOTOR DYSFUNCTION; MOUSE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA;

EID: 84992187323     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyw047     Document Type: Article

References (43)

1. Banerjee R, Beal MF, Thomas B (2010) Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci 33(12):541549.
2. Cao JJ, Li KS, Shen YQ (2011) Activated immune cells in Parkinson's disease. J Neuroimmune Pharmacol 6(3):323-329.
3. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH (2005) Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev 48(1):16-42.
4. Chao Y, Wong SC, Tan EK (2014) Evidence of inflammatory system involvement in Parkinson's disease. Biomed Res Int 2014:308654.
5. Cho DH, Nakamura T, Lipton SA (2010) Mitochondrial dynamics in cell death and neurodegeneration. Cell Mol Life Sci 67(20):3435-3447.
6. Choi JS, Park C, Jeong JW (2010) AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys Res Commun 391(1):147-151.
7. Chung YC, Kim SR, Jin BK (2010) Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 185(2):1230-1237.
8. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, Vila M (2010) Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 30(37):12535-12544.
9. Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B, Menendez JA (2011) Metformin: multi-faceted protection against cancer. Oncotarget 2(12):896-917.
10. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, Taylor R, Asara JM, Fitzpatrick J, Dillin A, Viollet B, Kundu M, Hansen M, Shaw RJ (2011) Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331(6016):456-461.
11. Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8(10):774-785.
12. Hardie DG (2008) AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 32 Suppl 4:S7-12.
13. Hu LF, Lu M, Tiong CX, Dawe GS, Hu G, Bian JS (2010) Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. Aging Cell 9(2):135-146.
14. Imfeld P, Bodmer M, Jick SS, Meier CR (2012) Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J Am Geriatr Soc. 60:916-921.
15. Jara JA, Lopez-Munoz R (2015) Metformin and cancer: between the bioenergetic disturbances and the antifolate activity. Pharmacol Res.
16. Jung SN, Yang WK, Kim J, Kim HS, Kim EJ, Yun H,Park H, Kim SS, Choe W, Kang I, Ha J (2008) Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis 29(4):713-721.
17. Khang R, Park C, Shin JH (2015) Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice. Neuroscience 294:182-192.
18. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, Kohler A, Glossmann H, Schneider R, Sutherland C, Schweiger S (2010) Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A 107(50):21830-21835.
19. Li J, Deng J, Sheng W, Zuo Z (2012) Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav 101(4):564-574.
20. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, Robinson JP (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278(10):8516-8525.
21. Li X, Zhen D, Lu X, Xu H, Shao Y, Xue Q, Hu Y, Liu B, Sun W (2010) Enhanced cytotoxicity and activation of ROS-dependent c-Jun NH2-terminal kinase and caspase-3 by low doses of tetrandrine-loaded nanoparticles in Lovo cells-a possible Trojan strategy against cancer. Eur J Pharm Biopharm 75(3):334-340.
22. Lu M, Hu G (2012) Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies. Clin Exp Pharmacol Physiol 39(6):577-585.
23. Lynch-Day MA, Mao K, Wang K, Zhao M, Klionsky DJ (2012) The role of autophagy in Parkinson's disease. Cold Spring Harb Perspect Med 2(4):a009357.
24. Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, Hoyt KR (2007) Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci Lett 411(2):98-103.
25. Menzies FM, Fleming A, Rubinsztein DC (2015) Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci 16(6):345-357.
26. Moon HE, Paek SH (2015) Mitochondrial Dysfunction in Parkinson's Disease. Exp Neurobiol 24(2):103-116.
27. Morris JK, Bomhoff GL, Stanford JA, Geiger PC (2010) Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 299(4):R1082-1090.
28. Pan T, Kondo S, Le W, Jankovic J (2008) The role of autophagylysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131(Pt 8):1969-1978.
29. Panicker GK, Karnad DR, Salvi V, Kothari S (2012) Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs. J Assoc Physicians India 60:56-61.
30. Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S (2014) Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience 277:747-754.
31. Perier C, Vila M (2012) Mitochondrial biology and Parkinson's disease. Cold Spring Harb Perspect Med 2(2):a009332.
32. Poewe W, Djamshidian-Tehrani A (2015) Movement disorders in systemic diseases. Neurol Clin 33(1):269-297.
33. Rojas LB, Gomes MB (2013) Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 5(1):6.
34. Rubinsztein DC, Bento CF, Deretic V (2015) Therapeutic targeting of autophagy in neurodegenerative and infectious diseases. J Exp Med 212(7):979-990.
35. Savitt JM, Dawson VL, Dawson TM (2006) Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116(7):1744-1754.
36. Sun XL, Liu Y, Dai T, Ding JH, Hu G (2011) Uncoupling protein 2 knockout exacerbates depression-like behaviors in mice via enhancing inflammatory response. Neuroscience 192:507-514.
37. Van Der Brug MP, Singleton A, Gasser T, Lewis PA (2015) Parkinson's disease: from human genetics to clinical trials. Sci Transl Med 7(305):205ps220.
38. Volta M, Milnerwood AJ, Farrer MJ (2015) Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease. Lancet Neurol 14(10):1054-1064.
39. Wang L, Zhai YQ, Xu LL, Qiao C, Sun XL, Ding JH, Lu M, Hu G (2014) Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp Neurol 251:22-29.
40. Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR, Carlson M, Carling D (2005) Ca2+/calmodulindependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2(1):21-33.
41. Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, Jankovic J, Pan T (2011) Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 19(3):163-174.
42. Xilouri M, Stefanis L. (2015) Chaperone mediated autophagy to the rescue: a new-fangled target for the treatment of neurodegenerative diseases. Mol Cell Neurosci 66(Pt A):29-36.
43. Zhou R, Yazdi AS, Menu P, Tschopp J (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469(7329):221-225.